Manulife Financial is turning to the U.S. debt market to strengthen its regulatory capital position, pricing a $750 million subordinated notes offering that is expected to qualify as Tier 2 capital.

The Canadian insurer priced the notes at par with a fixed annual coupon of 6.146%. The securities are expected to be issued on September 11, 2026, and will mature in 2041.

The transaction gives Manulife another source of long-duration funding while adding capital that can absorb losses within the regulatory framework applicable to large financial institutions.

The move is less about raising money for a specific operating initiative than maintaining balance-sheet flexibility. Manulife says net proceeds will be used for general corporate purposes, including potential future refinancing requirements.

A capital raise designed for regulatory requirements

Subordinated debt occupies a different position from conventional senior corporate borrowing.

If an insurer enters financial distress, subordinated creditors rank behind senior creditors in the repayment hierarchy. That additional risk is one reason regulators can recognize qualifying subordinated instruments as part of an insurer’s capital resources.

Manulife expects the new notes to qualify as Tier 2 regulatory capital.

For insurers, regulatory capital is designed to provide a financial buffer against unexpected losses and support the company’s ability to meet obligations to policyholders. Maintaining sufficient capital also gives institutions greater flexibility as their businesses grow, markets change and existing debt approaches maturity.

The $750 million issuance therefore adds to Manulife’s broader capital-management toolkit rather than representing a conventional funding round for expansion.

The economics change in 2036

The notes have a relatively unusual two-stage interest structure.

From the September 11, 2026 issue date through September 10, 2036, investors will receive a fixed annual coupon of 6.146%.

Beginning on the September 11, 2036 reset date, the interest rate will change to the applicable CMT Rate plus a 1.350% spread through maturity in 2041.

That reset structure gives investors a combination of a decade of fixed income and subsequent exposure to prevailing benchmark rates.

For Manulife, the structure also means the economic cost of the capital can change after the reset date. The company has specified circumstances under which it can redeem the notes, subject to regulatory approval.

The Superintendent of Financial Institutions Canada must approve applicable redemptions, reinforcing the regulatory character of the instrument.

Why Tier 2 capital matters for insurers

Tier 2 capital generally serves as a secondary layer of financial protection within an insurer’s capital framework.

Unlike common equity, subordinated debt has a defined maturity and contractual interest payments. Yet qualifying instruments can still contribute to regulatory capital because their subordinated structure provides additional loss-absorption capacity.

For investors, that creates a different risk-return profile from both equity and senior debt.

For insurers, the ability to issue qualifying subordinated securities provides another mechanism for managing capital without relying exclusively on common equity.

That flexibility becomes particularly relevant when insurers are balancing growth, shareholder returns, acquisitions, debt refinancing and regulatory capital requirements.

A long-dated liability with refinancing flexibility

The 2041 maturity gives Manulife a long-dated funding source, while the 2036 reset date and redemption provisions create additional flexibility.

The company can redeem the notes, subject to regulatory approval, in specified circumstances. Those include certain opportunities around the reset date as well as defined regulatory and tax events.

Such provisions are common features of regulatory capital instruments because both investors and regulators need clarity around when an issuer can retire securities that count toward capital.

For Manulife, the structure provides a way to manage the liability over a long horizon while preserving options as its capital needs and market conditions evolve.

U.S. investors remain an important funding source

The offering was made in the United States under Manulife’s SEC-registered securities program.

Four major investment banks—BofA Securities, Citigroup Global Markets, J.P. Morgan Securities and Morgan Stanley—served as joint book-running managers.

The transaction illustrates the depth of the U.S. institutional debt market for large financial issuers outside the United States.

For Canadian financial institutions, access to multiple capital markets can broaden the investor base and provide additional flexibility when pricing regulatory capital.

The decision to issue in U.S. dollars also introduces another dimension to balance-sheet management. The currency, pricing and eventual refinancing requirements all have to be considered alongside Manulife’s broader asset and liability profile.

What the transaction says about insurer capital strategy

The issuance comes at a time when insurers are operating in a financial environment shaped by changing interest rates, evolving capital rules and continued demand for balance-sheet resilience.

Capital requirements are not simply a regulatory constraint. They influence how insurers finance growth, structure acquisitions, manage dividends and determine the mix of debt and equity on their balance sheets.

That makes regulatory capital markets an important part of the broader financial technology and banking infrastructure story.

Although the transaction itself is straightforward—a $750 million subordinated debt offering—the underlying strategy is more consequential. Large insurers increasingly need to manage capital across multiple jurisdictions, funding currencies and regulatory frameworks while maintaining sufficient buffers for policyholder obligations.

The broader financial-services technology connection

There is also a technology layer beneath increasingly sophisticated capital management.

Large insurers rely on increasingly integrated systems for capital modeling, liquidity forecasting, risk management, regulatory reporting and asset-liability management. Those systems allow finance and risk teams to model how new debt affects capital ratios, funding costs and future refinancing requirements.

As financial institutions adopt more advanced analytics and AI, capital planning is becoming increasingly data-driven. The value is not necessarily in automating the issuance itself, but in giving finance teams faster visibility into how different funding decisions affect the balance sheet under changing market and regulatory scenarios.

Manulife’s latest issuance is therefore both a capital-markets transaction and a balance-sheet management exercise.

The $750 million notes add another layer of regulatory capital while giving the insurer long-term funding capacity. For investors, the 6.146% initial coupon provides the immediate economics; for Manulife, the more important consideration is how the instrument fits into the company’s capital structure through 2041.

Market Landscape

The transaction sits within the broader market for insurance regulatory capital, subordinated debt and financial-institution funding.

Large insurers typically use a combination of common equity, retained earnings, senior debt and subordinated instruments to maintain financial flexibility. Qualifying Tier 2 securities are particularly useful because they can contribute to regulatory capital while avoiding the immediate dilution associated with issuing common shares.

For investors, subordinated insurance debt generally sits between senior debt and equity in terms of risk. Its appeal depends on coupon income, issuer credit quality, maturity, subordination and the regulatory treatment of the instrument.

The 6.146% initial coupon also reflects the broader interest-rate environment and investor demand for long-duration financial-sector credit. After 2036, the notes’ coupon becomes linked to the CMT Rate plus a fixed spread, shifting part of the interest-rate exposure.

The larger trend is toward increasingly sophisticated capital management as insurers balance regulatory requirements, funding costs, shareholder distributions and long-term liabilities.

Top Insights

• Manulife has priced $750 million of subordinated notes, providing additional long-term funding while supporting the insurer’s expected Tier 2 regulatory capital position.
• The securities carry a 6.146% fixed coupon through 2036, after which the rate resets to the applicable CMT Rate plus a 1.350% spread.
• The offering is primarily a capital-management transaction, with proceeds designated for general corporate purposes and potential future refinancing rather than a specific expansion project.
• Regulatory approval governs key redemption provisions, reflecting the special role subordinated debt plays in an insurer’s capital structure.
• The deal highlights the importance of diversified funding markets, with Manulife accessing U.S. institutional investors for a long-duration regulatory capital instrument.

Get in touch with our fintech expert